Xiamen Innovax Biotech Co., Ltd.

About us

Established in March 2005 with a registered capital of RMB 1.2 billion, Xiamen Innovax Biotech Co., Ltd. (“Innovax” or “we”) is the key vaccine arm of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., which is a famous company under Yangshengtang group. Innovax is the only private-owned technology enterprise engaged in vaccine R&D and production in Fujian Province, and the leader in the field of Human Papillomavirus (HPV) vaccines in China.

Since its establishment, Innovax has been devoted to the vaccine industry for nearly 20 years and committed to providing high-quality, affordable and innovative vaccines for humans.

Main Product

Hecolin? Cecolin? 9-Valent HPV Vaccine New-Generation HPV Vaccine Novel Rotavirus Vaccine 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Hecolin?

As the world's only HEV vaccine, Hecolin? hepatitis E vaccines vaccine was launched in October 2012.?Being the first viral vaccine developed with E. coli expression system, Hecolin? HEV vaccine completely reversed the perception the global academic community holds that “the prokaryotic system cannot be used for the development of virus vaccines”.

Cecolin?

As China’s first HPV vaccine, Cecolin? HPV 16&18 vaccine was approved by the National Medical Products Administration on December 30, 2019, which made China the third country in the world that can achieve independent supply of HPV vaccines, following only the United States and the United Kingdom.

9-Valent HPV Vaccine

New-Generation HPV Vaccine

Novel Rotavirus Vaccine

20-Valent Pneumococcal Polysaccharide Conjugate Vaccine